El interés en corto de Xtrackers RREEF Global Natural Resources ETF da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Xtrackers RREEF Global Natural Resources ETF. Los datos de interés en corto se actualizan cada dos semanas.

Xtrackers RREEF Global Natural Resources ETF (NASDAQ:NRES), Informe de interés en corto

Basic Materials

Energy

Consumer Defensive

Real Estate

Industrials

Under normal circumstances, the fund invests at least 80 percent of its net assets, plus the amount of any borrowings for investment purposes (calculated at the time of any investment), in securities of companies in the natural resources sector. For purposes of the funds 80 percent investment policy, the natural resources sector includes companies belonging to one of the following Global Industry Classification Standard (GICS) categories: (i) Agriculture: Agricultural Products & Services, Fertilizers & Agricultural Chemicals, Forest Products, Paper & Plastic Packaging Products & Materials, Paper Products and Timber REITs ; (ii) Oil and Gas: Integrated Oil & Gas, Oil & Gas Drilling, Oil & Gas Exploration & Production, Oil & Gas Refining & Marketing and Oil & Gas Equipment & Services; (iii) Coal: Coal & Consumable Fuels; (iv) Industrial Metals: Aluminum, Diversified Metals & Mining, Steel and Copper; and (v) Precious Metals: Gold, Precious Metals & Minerals and Silver. The fund may invest in companies of any market capitalization.

Glencore International Plc

Total Energies Se

Exxon Mobil Corp.

Nutrien Ltd

Corteva Inc.

Upm-kymmene Oyj

Gold Fields Limited, Adr

Shell plc

Smurfit Westrock Plc

Canadian Natural Resources Ltd.

Newmont Corp.

Xtrackers RREEF Global Natural Resources ETF

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are trading lower Monday after Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) terminated its collaboration <a href="https://www.benzinga.com/pressreleases/25/06/n46049309/novo-nordisk-terminates-collaboration-with-hims-hers-health-inc-due-to-concerns-about-their-illega">with the company</a>. 
What Happened: Novo Nordisk announced Monday that it will no longer be working with Hims &amp; Hers Health. As a result, the company will no longer have direct access to Wegovy through the NovoCare Pharmacy. 
Novo Nordisk alleged in a press release that Hims &amp; Hers Health has failed to follow laws that prohibit mass sales of compounded drugs under the false appearance of &#8220;personalization&#8221; and has used deceptive marketing with disregard for patient safety.
&#8220;Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy,&#8221; said&nbsp;Dave Moore, executive vice president of Novo Nordisk&#8217;s U.S. operations.
&#8220;We will work with telehealth companies to provide direct access to Wegovy&nbsp;that share our commitment to patient safety – and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action.&#8221;
The news comes after the U.S. Food and Drug Administration's (FDA)&nbsp;said in April that Semaglutide, the active ingredient in popular weight-loss drugs like Wegovy, could&nbsp;<a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize" target="_blank" rel="noreferrer noopener">no longer be offered</a>&nbsp;in compounded drugs by outsourcing facilities.
Shares of Hims &amp; Hers Health fell as the FDA action took effect. Hims &amp; Hers sells cheaper versions of popular weight-loss drugs, known as compounded drugs. Regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage. The company generated over $225 million in revenue in 2024 from its GLP-1 product.
Novo Nordisk on Monday said it&#8217;s &#8220;deeply concerned&#8221; and will continue to take proactive measures to keep U.S. patients safe from &#8220;knock-off drugs made with foreign illicit active pharmaceutical ingredients.&#8221;
HIMS Price Action:&nbsp;<a href="http://benzinga.com/quote/hims" target="_blank" rel="noreferrer noopener">Hims &amp; Hers Health shares</a>&nbsp;were down 23.9% at $48.90 at the time of publication Monday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46048974/eli-lillys-investigational-oral-pill-shows-weight-loss-benefits-with-lingering-side-effect-concerns">Eli Lilly&#8217;s Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46048611/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-7">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo: Lori Butcher/Shutterstock.

News

Movers

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and raises the price target from $73 to $82.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Kroger, Raises Price Target to $82

JMP Securities analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Market Outperform and maintains $89 price target.

Reiteration

GPCR

JMP Securities Reiterates Market Outperform on Structure Therapeutics, Maintains $89 Price Target

Micropolis Holding Co. ("Micropolis" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#NYSE">MCRP</a>), a pioneer in unmanned ground vehicles and AI-driven security solutions, today announced it has changed the legal name of its wholly-owned subsidiary from Micropolis Digital Development FZ-LLC to Micropolis Robotics FZ-LLC. This move is a result of the Company's growing portfolio of autonomous robotic platforms and corporate milestones, including its collaboration with SEE Holding Ltd at The Sustainable City 2.0 and Memorandum of Understanding with Emirates Steel (EMSTEEL), a leading UAE-based steel and construction materials manufacturer.

MCRP

Micropolis Holding Changes Legal Name Of Its Wholly-Owned Subsidiary From Micropolis Digital Development FZ-LLC To Micropolis Robotics FZ-LLC

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is trading near our pivot at 593.73. Bulls want immediate upside pressure above 595.14, maintaining that level as firm support. Should buyers show strength, the next move targets 596.57. With solid demand, expect further upside testing 598.04 and potentially our ultimate bullish objective today at 599.24.&nbsp;
If bulls falter at 593.73, bears will aim lower towards 592.00. Strong selling at this juncture brings 589.71 into focus. A breakdown below here with sustained pressure likely drags price to 587.31. In an aggressive bearish scenario, anticipate price action moving down to our lowest bearish level today at 585.75.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently positioned at our crucial reference point of 525.19. Bulls seek firm buying above 527.03, establishing that as sturdy support. Further bullish action elevates price toward 528.44. Should buyers persist, expect continuation higher to 530.70. A vigorous upward push can extend price toward 532.52, ultimately reaching today&#8217;s bullish target at 533.70.&nbsp;
If price fails to sustain above 525.19, look for bears to seize control, initially testing 523.91. Weaker price action here will target a decline toward 522.57. If selling intensifies, bears will aim for the deeper support level of 521.15. Should this level collapse under selling pressure, expect a further move downward toward today's bearish target of 519.87.
Apple Inc. (AAPL)
Apple is auctioning near our anchor at 200.53. Bulls must sustain this as solid support, initiating a climb toward 202.29. Continued bullish flows could drive price upwards to 203.48. Sustained buyer engagement throughout the session may propel Apple toward our ultimate bullish price objective at 204.33.&nbsp;
If the level at 200.53 weakens, expect bears to press downward initially targeting 199.51. A breakdown with continued selling suggests a further move toward 198.79. Additional selling intensity puts pressure on 198.22. Should bears maintain dominance, the auction could continue downward to our bearish target at 197.69.
Microsoft Corp. (MSFT)
Microsoft is trading near our pivotal area of 476.18. Bulls aim to sustain momentum above this level, pushing upward toward 477.66, establishing firm intraday support. Persistent bullish action here would next target the upside level of 478.82. Robust demand could lead Microsoft to our highest bullish target today at 480.04.&nbsp;
A failure at 476.18 shifts control to bears, targeting the downside level at 474.99 initially. Continued bearish activity would prompt further selling toward 473.80. Should selling intensify, anticipate price dropping toward the deeper support at 472.91. If bearish sentiment dominates today&#8217;s session, our ultimate downside target is positioned at 472.11.
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
NVIDIA is auctioning close to our focal area at 143.41. Bulls seek immediate upward momentum toward 144.21, aiming to firmly establish it as support. Strong buying pressure may drive price upward to 145.61. If buying volume accelerates, expect further upside toward 147.06, potentially reaching today&#8217;s bullish goal at 148.52.&nbsp;
Weakness below 143.41 opens the door for bears targeting the downside at 142.35. Continued selling would next challenge support at 141.21. Further weakening could see the auction descend toward 140.28. Sustained selling pressure may ultimately drive price action toward our lower bearish level today at 139.42.
Alphabet Inc Class A (GOOGL)
Alphabet is trading near our central pivot at 167.04. Bulls require a solid defense of this area to advance upward, initially targeting 169.34. Persistent bullish engagement may elevate price toward today&#8217;s highest bullish objective of 171.14.&nbsp;
If 167.04 fails as support, bears will likely press downward first to 165.41. Further selling pressure opens a pathway to test lower at 163.79. In a scenario of aggressive downside activity, price could reach our bearish target today at 161.79.
Meta Platforms Inc (META)
Meta is hovering around our important level of 683.97. Bulls aim to firmly hold this position and aggressively drive upward toward 689.09. Continued robust demand may further lift the price toward 692.10. Sustained bullish sentiment throughout today&#8217;s auction could potentially achieve our ultimate bullish target at 695.62.&nbsp;
If 683.97 support breaks, expect bears to aggressively target downside movement toward 679.79. Increasing selling pressure would next seek support at 676.46. Should sellers maintain dominance, anticipate continued downward momentum toward our lowest bearish objective today at 671.80.
Tesla Inc. (TSLA)
Tesla is trading near our crucial pivot of 322.52. Bulls must quickly move upward toward 327.59 to establish bullish momentum. Ongoing buying pressure can carry Tesla's price toward the key resistance area at 333.93. A sustained bullish environment might lead to further testing upwards at 340.97, ultimately targeting our peak bullish price today at 346.64.&nbsp;
Weakness at 322.52 would prompt bears to drive prices lower initially toward 315.93. Continued selling would challenge the next support level at 312.42. A breakdown under persistent bearish pressure would likely move price action down to our lowest bearish target today at 310.17.
Final Word: Today&#8217;s market activity begins with significant economic releases, starting with June's preliminary S&amp;P Global Manufacturing PMI at 9:45 AM ET, followed shortly by May's Existing Home Sales data at 10:00 AM ET. Given current geopolitical tensions escalating in the Middle East, heightened volatility across equity markets is expected. This environment may yield sudden intraday swings, thus requiring traders to remain agile, disciplined, and well-prepared. Monitor these events carefully, adjusting risk appropriately. Trade safely, focus on key price levels, and best of luck today!
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

Markets

Trading Ideas

NVDA

How To Trade SPY, Top Tech Stocks Using Technical Analysis

Board of Directors Announces Restructuring Plan
Tel Aviv, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- ZOOZ Power (Nasdaq and TASE: ZOOZ), a leading provider of flywheel-based power boosters and energy management systems for enabling ultra-fast EV charging solutions, announced today that its board of directors has approved a plan to explore additional strategic alternatives to fully capitalize on its advanced, patented flywheel technology.
Over the past several months, ZOOZ Power has engaged in ongoing discussions with a prominent defense and intelligence electronics company regarding deployment of a robust, repetitive short-duration power booster capable of operating in challenging environments. ZOOZ Power is currently conducting a proof of concept (POC) with this defense company — a collaboration that has the potential to unlock new verticals and significantly broaden the application of its flywheel technology.
As part of the efforts to enhance execution, the board has also approved a company-wide cost reduction and restructuring initiative designed to reduce operating costs by approximately 35%. These cost efficiencies will enable greater business flexibility.

ZOOZ

ZOOZ Power Board Approves Plan To Explore Additional Strategic Alternatives To Fully Capitalize On Advanced, Patented Flywheel Technology

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">89.28</td>
<td align="right">0.3</td>
<td align="right">0.33</td>
<td>349.3K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.148800</td>
<td align="right">-0.871</td>
<td align="right">-1.08</td>
<td>1.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.460000</td>
<td align="right">-0.370</td>
<td align="right">-0.89</td>
<td>779</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.300000</td>
<td align="right">-0.480</td>
<td align="right">-0.60</td>
<td>9.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">85.982113</td>
<td align="right">-0.438</td>
<td align="right">-0.51</td>
<td>113</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">131.980000</td>
<td align="right">-0.620</td>
<td align="right">-0.47</td>
<td>9.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">209.940000</td>
<td align="right">-0.740</td>
<td align="right">-0.36</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.200000</td>
<td align="right">-0.160</td>
<td align="right">-0.32</td>
<td>134.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">102.570000</td>
<td align="right">-0.270</td>
<td align="right">-0.27</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">240.530000</td>
<td align="right">-0.010</td>
<td align="right">-0.01</td>
<td>92.6K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 23, 2025

On Sunday, The New England Journal of Medicine (NEJM) published results from Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">phase 3 REDEFINE 1 trial</a> of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">weight-related medical</a> complication and without diabetes.
CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analog, cagrilintide. 
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/45927887/novo-nordisk-moves-amycretin-into-phase-3-trials-for-weight-management-becomes-europes-largest-company" target="_blank" rel="noreferrer noopener">Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe&#8217;s Largest Company</a>
<h2 class="wp-block-heading">REDEFINE 1 Trial</h2>
If all patients adhered to treatment, CagriSema <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916353" rel="noreferrer noopener">resulted</a> in a greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group.
When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved a statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group.
In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI &lt; 30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment.
In the placebo group,10.2% reached that threshold at 68 weeks.
Select confirmatory secondary endpoints showed that if all participants adhered to treatment, 40.4% of those receiving CagriSema achieved a weight reduction of ≥25%.
Additionally, 23.1% lost ≥30% of their body weight.
When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction, and 19.3% achieved ≥30%.
In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus –5.7% and –4.3% for the placebo group, respectively.
These data, along with the related <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44244966/novo-nordisks-combo-drug-cagrisema-shows-16-weight-reduction-in-second-phase-3-trial-stock-falls" rel="noreferrer noopener">phase 3 REDEFINE 2 study</a> conducted in adults with overweight or obesity and type 2 diabetes, were presented at the American Diabetes Association.
<h2 class="wp-block-heading">REDEFINE 2 Study</h2>
If all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was –15.7% with CagriSema versus –3.1% with placebo.
When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was –13.7% with CagriSema versus –3.4% with placebo.
A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by &gt;5% (83.6% vs. 30.8% of participants), ≥10% (65.6% vs. 10.3%), ≥15% (43.9% vs. 2.4%), and ≥20% (22.9% vs. 0.5%;)
The safety results from CagriSema in REDEFINE 2 were similar to those reported in the REDEFINE 1 trial.
Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2.
<h2 class="wp-block-heading">Market Reaction</h2>
NVO experienced a decline of over 7% in premarket trading on Monday; the market&#8217;s reaction suggests that Novo Nordisk&#8217;s CagriSema has been perceived to have a less favorable side effect profile when compared to Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) orforglipron.
In Eli Lilly&#8217;s ACHIEVE-1 trial, the most common adverse events for participants treated with orforglipron (3 mg, 12 mg and 36 mg, respectively) were diarrhea (19%, 21% and 26%) vs. 9% with placebo, nausea (13%, 18% and 16%) vs. 2% with placebo, dyspepsia (11%, 20% and 15%) vs. 7% with placebo, constipation (8%, 17% and 14%) vs. 4% with placebo, and vomiting (5%, 7% and 14%) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46041936/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-inj" rel="noreferrer noopener">vs. 1% with placebo</a>.
In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs. 39.9% with placebo), including nausea (55% vs. 12.6 %), constipation (30.7% vs. 11.6%), vomiting (26.1% vs. 4.1%) and mainly were transient and mild-to-moderate in severity.
Adding to the investor concerns, William Blair analysts expressed disappointment, stating, &#8220;We had hoped that the amylin component could provide a higher magnitude of weight loss among patients living with type 2 diabetes. Unfortunately, the hypothesis did not come to fruition, and in our view, there is no evidence to suggest CagriSema should be prescribed over Zepbound in any subpopulation, based on the available data released to date.&#8221;
Analyst Andy Hsieh further elaborated that the &#8220;high frequency of adverse events could fuel uncertainty over the asset&#8217;s differentiation against approved (Zepbound) or late-stage investigational (retatrutide and MariTide) compounds.&#8221;
Price Action: At the last check on Monday, NVO stock was down 7.10% to $68.53 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46048974/eli-lillys-investigational-oral-pill-shows-weight-loss-benefits-with-lingering-side-effect-concerns">Eli Lilly&#8217;s Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns</a></li>
</ul>
Image via Shutterstock

Analyst Color

Biotech

Large Cap

Health Care

General

Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern

Macro Economic Events

Global

Economics

US Assesses High Risk Of Iranian Retaliation Against US Forces Soon, Still Pursuing Diplomatic Resolution, Two US Officials Say; Iranian Retaliation Could Come As Soon As Next Day Or Two, One Of The Officials Say

WIIM

Standard BioTools shares are trading higher after the company announced a strategic sale of SomaLogic to Illumina.

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients
NASHVILLE, Tenn., June 23, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>),&nbsp;a specialty pharmaceutical company committed to developing new products for rare diseases, shared the latest positive results from its <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4453941-1&amp;h=432605532&amp;u=https%3A%2F%2Fwww.fightdmdtrial.com%2F&amp;a=Phase+2+FIGHT+DMD+trial">Phase 2 FIGHT DMD trial</a> evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Las Vegas. These new results highlight multiple indicators of cardiac benefit with ifetroban treatment in DMD heart disease, the leading cause of death in DMD, including previously unreported pharmacokinetic findings and cardiac biomarker data that demonstrate the drug's potential to prevent ongoing heart damage.

CPIX

Cumberland Pharma Presents Latest Results From Phase 2 FIGHT DMD Trial Evaluating Ifetroban, Oral Therapy For DMD Heart Disease, At PPMD Conference In Las Vegas

ILMN

CORRECTION: Standard BioToles Ticker Is "LAB" Not "ILMN"

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25%
As recently <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively; data from the third patient enrolled is expected
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 23, 2025 / <a href="https://pr.report/bqbi">Jaguar Health, Inc.</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) today provided updates on the company's orphan disease intestinal failure program. Jaguar, through Jaguar family companies <a href="https://pr.report/bqbk">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/bqbl">Napo Therapeutics</a>, is currently supporting two independent proof-of-concept investigator-initiated trials (IITs), and conducting two placebo-controlled Phase 2 studies, of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) in the United States, European Union, and/or Middle East/North Africa regions.
Completion of Napo's randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients is expected in mid-2026 as planned.

JAGX

Jaguar Health Updates On Orphan Disease Intestinal Failure Program; Completion Of Napo's Phase 2 Study Of Crofelemer In Pediatric MVID Patients Is Expected In Mid-2026 As Planned

JMP Securities analyst Patrick Walravens reiterates Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) from Market Perform to Market Perform.

ADBE

JMP Securities Reiterates Market Perform on Adobeto Market Perform

Barrington Research analyst Vincent Colicchio maintains TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) with a Outperform and maintains $156 price target.

Barrington Research Maintains Outperform on TD Synnex, Maintains $156 Price Target

<a href="https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html" title="https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html">https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html</a>

Libertas Bio Licenses Gusacitinib To Sanofi

Management

Cushman & Wakefield Announces Retirement Of Brett White As Chairman; Appoints Steve Plavin As Chairman And Independent Director

Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery System
<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4453227-1&amp;h=3153541511&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a>&nbsp;("Genprex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago. These studies used an alternative second-generation approach with a non-viral lipid nanoparticle delivery system. This exploratory research represents the Company's forward-thinking work within its diabetes program to determine if the novel diabetes gene therapy can be delivered using a non-viral delivery system which could allow for repeat dosing.
 &nbsp;

GNPX

Genprex Announces That Its Research Collaborators Presented Positive Preclinical Data And Research From Studies Of Gpx-002 At The 2025 American Diabetes Association 85th Scientific Session In Chicago

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg&#8216;s apparent alignment with the MAGA movement has left many of his colleagues feeling &#8220;grieving,&#8221; and Elon Musk&#8216;s popularity was reportedly a major motivating factor behind this.
What Happened: Zuckerberg&#8217;s growing alignment with the Trump administration led to a radical transformation, leaving his employees feeling betrayed. On the other hand, some saw it as a natural transition for the Meta CEO, <a href="https://www.ft.com/content/8e7e6f5f-6f7b-4c7f-8e5e-7c9e4c1e2d8b">as</a> per the Financial Times report.
According to insiders at Meta Platforms, Zuckerberg&#8217;s shift into &#8220;MAGA Mark&#8221; was attributed to Zuckerberg&#8217;s desire to be seen as a bold and visionary innovator, a status he felt Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Musk had achieved. &#8220;He saw that Elon Musk was popular among the tech bros. There was a push to make him cool,&#8221; one source revealed.
Meta did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Some employees also recalled how Zuckerberg, in a bid to emulate Musk&#8217;s strategies, announced significant layoffs at Meta soon after Elon Musk slashed the workforce following the Twitter acquisition in 2022.
In a surprising move in January, ahead of Donald Trump&#8216;s second term inauguration,&nbsp;Zuckerberg announced that Meta's moderation&nbsp;would be relaxed and professional fact-checking would be done away with. Efforts towards diversity, equity, and inclusion would also be scaled back.
These actions have left many employees feeling betrayed, with some describing their feelings&nbsp;as "grieving", "horror" and "betrayal".&nbsp;Roger McNamee, an early investor&nbsp;turned critic, said&nbsp;Zuckerberg has become "unbelievably sensitive&nbsp;to not becoming irrelevant".
Some also believe that Trump&#8217;s warning to pursue 2020 &#8216;Election Fraudsters,&#8217; particularly Zuckerberg, also motivated the Meta CEO to warm up to Trump.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/politics/25/06/46046249/mike-pence-lauds-trumps-decisive-leadership-on-the-historic-mission-against-irans-nuclear-program-i-couldnt-be-more-proud" target="_blank" rel="noreferrer noopener">Mike Pence Lauds Trump&#8217;s &#8216;Decisive Leadership&#8217; On The &#8216;Historic Mission&#8217; Against Iran&#8217;s Nuclear Program: &#8216;I Couldn&#8217;t Be More Proud&#8217; &#8211; Benzinga</a>
Why It Matters: Zuckerberg&#8217;s evolving image and actions have been a topic of interest in recent months. Despite the controversy surrounding his public persona, Meta has been making significant moves in the tech industry and his aggressively pushed into artificial intelligence (AI). 
Recently, Sam Altman revealed how Zuckerberg&#8217;s company&nbsp;reportedly offered<a href="https://www.benzinga.com/markets/tech/25/06/45988600/mark-zuckerbergs-meta-dangled-100-million-signing-bonuses-to-openai-team-members-says-sam-altman-happy-none-of-our-best-people-took-them"> $100 million compensation</a> packages&nbsp;to lure top OpenAI talent. Furthermore,&nbsp;Meta was in talks to hire Nat Friedman, former CEO of GitHub, <a href="https://www.benzinga.com/markets/tech/25/06/46010604/mark-zuckerbergs-meta-reportedly-looking-to-hire-former-github-ceo-nat-friedman-and-investor-daniel-gross-as-part-of-aggressive-ai-expansion-strategy">to bolster</a> its AI efforts.&nbsp;
As for political alignment, Zuckerberg continues to endorse the Trump administration. In March, Trump also suggested that Meta may invest up to $60 billion in the U.S. by the end of the year amid the President&#8217;s &#8220;America-First&#8221; goal. Meanwhile, Elon Musk has currently distanced himself from politics following a feud with President Trump and vowed to focus on his business ventures.
On a year-to-date basis, Meta surged 13.44%, while Tesla slumped over 15%, as per <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/politics/25/06/46044108/outrage-mounts-over-trumps-appointment-of-22-year-old-to-terrorism-unit-amid-iran-crisis" target="_blank" rel="noreferrer noopener">Outrage Mounts Over Trump&#8217;s Appointment of 22-Year-Old to Terrorism Unit Amid Iran Crisis</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

TSLA

Mark Zuckerberg's MAGA Pivot Driven By Elon Musk Envy, Image Goals, Say 'Betrayed' Meta Insiders: Report

<a href="https://pr.report/bq8h">WidePoint Corporation</a> (NYSE American:<a href="https://pr.report/bq8i">WYY</a>), the federally certified provider of Trusted Mobility Management (TM2) solutions, announced today that it has secured a one-year, $110,000 contract to deliver Device as a Service (DaaS) management and support for a prominent Federal health research agency. This initiative is aimed at streamlining the deployment and lifecycle management of cutting-edge technologies critical to advancing innovative health solutions. This award marks the first of several material DaaS opportunities in the pipeline in collaboration with the Company's strategic Fortune 500 partner.

Comments

Xtrackers RREEF Global Natural Resources ETF

Interés en corto

Xtrackers RREEF Global Natural Resources ETF (NASDAQ:NRES), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL